Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer
The purpose of this study is to determine whether the study drug is effective and safe in the treatment of patients with metastatic breast cancer
Breast Neoplasms|Breast Cancer, Metastatic
DRUG: Sagopilone (BAY86-5302, ZK 219477)|DRUG: Sagopilone (BAY86-5302, ZK 219477)|DRUG: Sagopilone (BAY86-5302, ZK 219477)|DRUG: Sagopilone (BAY86-5302, ZK 219477)
Tumor response rate (complete or partial response according to RECIST), The proportion of subjects with either complete or partial response according to the modified RECIST criteria was calculated as best overall response after 6 courses of therapy (i.e., before Course 7)., Every 6 weeks
Duration of complete or partial tumor response, Defined as the time between the first date that confirmed complete or partial response was established as "overall response" and the first date that recurrence or overall response of progressive disease was documented, Every 6 weeks|Time to tumor progression, Defined as the time from the start of study treatment to the first objective evidence of tumor progression, symptomatic deterioration, or death from cancer, Every 6 weeks
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.